{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:28Z","timestamp":1792787308397,"version":"4.5.0"},"reference-count":62,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2024NFSC1912"],"award-info":[{"award-number":["2024NFSC1912"]}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK064C"],"award-info":[{"award-number":["02NUK064C"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Provincial Research Foundation","award":["2026NSFSC0652"],"award-info":[{"award-number":["2026NSFSC0652"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The local effect of radiotherapy (RT) is enhanced by CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses elicited through dendritic cell (DC)-mediated cross-presentation of tumor antigens, facilitated by RT-induced damage-associated molecular patterns. The abscopal effect\u2014regression of non-irradiated tumors\u2014has been observed clinically, particularly in combination with immune checkpoint blockade, although it remains uncommon. To better understand how to enhance this effect, we investigated two RT\/\u03b1-programmed death 1 (PD-1)-based triple combinations incorporating either \u03b1-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD122-targeted interleukin (IL)-2 complexes (IL-2c).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We tested these regimens in B16 melanoma and C51 colon carcinoma models in mice with one irradiated and one non-irradiated tumor on opposite flanks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In both models, RT\/\u03b1PD-1\/\u03b1CTLA-4 elicited a stronger abscopal response than RT\/\u03b1PD-1\/IL-2c. In the C51 model, RT\/\u03b1PD-1\/\u03b1CTLA-4 achieved a 61.5% abscopal cure rate, dependent on both CD8\n                      <jats:sup>+<\/jats:sup>\n                      and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells. In contrast, the less effective RT\/\u03b1PD-1\/IL-2c response required only CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. The enhanced abscopal effect with RT\/\u03b1PD-1\/\u03b1CTLA-4 was associated with increased numbers, effector function, and reduced exhaustion of tumor-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      tumor-infiltrating lymphocytes (TILs) and of CD4\n                      <jats:sup>+<\/jats:sup>\n                      TILs, along with elevated CD80\n                      <jats:sup>+<\/jats:sup>\n                      CD86\n                      <jats:sup>+<\/jats:sup>\n                      DCs in abscopal tumors, as shown by flow cytometry; immunofluorescence confirmed increased T-cell infiltration. CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell depletion during RT\/\u03b1PD-1\/\u03b1CTLA-4 treatment impaired abscopal but not irradiated tumor control, reducing infiltration of tumor-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and conventional (c) DC1s, and diminishing cDC1-mediated cross-presentation in abscopal tumors. Activated CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells upregulated CD80\/CD86 on cDC1s and enhanced cross-presentation, partly via interferon-\u03b3 and tumor necrosis factor. Adoptively transferred tumor-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells from tumor-irradiated donors localized to unirradiated tumors and draining lymph nodes in \u03b1PD-1\/\u03b1CTLA-4-treated recipients, but not in untreated or CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cell-depleted mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These results demonstrate that an RT-based combination therapy that robustly induces CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells alongside CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells can elicit a strong abscopal response and suggest that CD4\n                      <jats:sup>+<\/jats:sup>\n                      effector T cells act at abscopal sites by promoting DC-mediated cross-presentation of tumor antigens to CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells originating from the irradiated tumor.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013055","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:45:43Z","timestamp":1770734743000},"page":"e013055","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["CD4\n                    <sup>+<\/sup>\n                    T cells facilitate the RT-induced abscopal effect by promoting antigen cross-presentation to CD8\n                    <sup>+<\/sup>\n                    T cells at unirradiated tumor sites"],"prefix":"10.1136","volume":"14","author":[{"given":"Xi","family":"Rao","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between DKFZ and Medical Center-University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-1861","authenticated-orcid":false,"given":"Kateryna","family":"Onyshchenko","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meidan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"Faculty of Biology, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegmar","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-1178","authenticated-orcid":false,"given":"Yizhou","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Gaedicke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between DKFZ and Medical Center-University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Firat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-5497","authenticated-orcid":false,"given":"Gabriele","family":"Niedermann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between DKFZ and Medical Center-University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026062607452307000_14.2.e013055.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6"},{"key":"2026062607452307000_14.2.e013055.2","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026062607452307000_14.2.e013055.3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026062607452307000_14.2.e013055.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00920-9"},{"key":"2026062607452307000_14.2.e013055.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2026062607452307000_14.2.e013055.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062607452307000_14.2.e013055.7","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026062607452307000_14.2.e013055.8","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"2026062607452307000_14.2.e013055.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.014"},{"key":"2026062607452307000_14.2.e013055.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011"},{"key":"2026062607452307000_14.2.e013055.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.025"},{"key":"2026062607452307000_14.2.e013055.12","doi-asserted-by":"crossref","first-page":"113501","DOI":"10.1016\/j.ejca.2023.113501","article-title":"The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?","volume":"198","author":"Di Giacomo","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026062607452307000_14.2.e013055.13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2-based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026062607452307000_14.2.e013055.14","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"JCO"},{"key":"2026062607452307000_14.2.e013055.15","unstructured":"Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer. Mural Oncology 2025. Available: https:\/\/ir.muraloncology.com\/news-releases\/news-release-details\/mural-oncology-provides-update-phase-3-artistry-7-trial"},{"key":"2026062607452307000_14.2.e013055.16","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.23.02082","article-title":"Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)","volume":"42","author":"Tannir","year":"2024","journal-title":"JCO"},{"key":"2026062607452307000_14.2.e013055.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37825-x","article-title":"Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice","volume":"14","author":"Onyshchenko","year":"2023","journal-title":"Nat Commun"},{"key":"2026062607452307000_14.2.e013055.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3451"},{"key":"2026062607452307000_14.2.e013055.19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature New Biol"},{"key":"2026062607452307000_14.2.e013055.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.11.002"},{"key":"2026062607452307000_14.2.e013055.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6"},{"key":"2026062607452307000_14.2.e013055.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80447-1"},{"key":"2026062607452307000_14.2.e013055.23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04651","article-title":"Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell\u2013dendritic cell interaction","volume":"440","author":"Castellino","year":"2006","journal-title":"Nature New Biol"},{"key":"2026062607452307000_14.2.e013055.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.12.002"},{"key":"2026062607452307000_14.2.e013055.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00787-3"},{"key":"2026062607452307000_14.2.e013055.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.10.008"},{"key":"2026062607452307000_14.2.e013055.27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature New Biol"},{"key":"2026062607452307000_14.2.e013055.28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature New Biol"},{"key":"2026062607452307000_14.2.e013055.29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.1.65"},{"key":"2026062607452307000_14.2.e013055.30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/imr.13301","article-title":"Decoding immunogenic cell death from a dendritic cell perspective","volume":"321","author":"Janssens","year":"2024","journal-title":"Immunol Rev"},{"key":"2026062607452307000_14.2.e013055.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(00)00191-6"},{"key":"2026062607452307000_14.2.e013055.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0"},{"key":"2026062607452307000_14.2.e013055.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062607452307000_14.2.e013055.34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683"},{"key":"2026062607452307000_14.2.e013055.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01061-1"},{"key":"2026062607452307000_14.2.e013055.36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature New Biol"},{"key":"2026062607452307000_14.2.e013055.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35615-5","article-title":"CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment","volume":"14","author":"Lei","year":"2023","journal-title":"Nat Commun"},{"key":"2026062607452307000_14.2.e013055.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.004"},{"key":"2026062607452307000_14.2.e013055.39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41423-024-01133-1","article-title":"CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors","volume":"21","author":"Lei","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026062607452307000_14.2.e013055.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.024"},{"key":"2026062607452307000_14.2.e013055.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116"},{"key":"2026062607452307000_14.2.e013055.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1344"},{"key":"2026062607452307000_14.2.e013055.43","doi-asserted-by":"publisher","DOI":"10.1038\/nri3152"},{"key":"2026062607452307000_14.2.e013055.44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8458"},{"key":"2026062607452307000_14.2.e013055.45","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.158"},{"key":"2026062607452307000_14.2.e013055.46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba5464","article-title":"Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity","volume":"12","author":"Raeber","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026062607452307000_14.2.e013055.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.023"},{"key":"2026062607452307000_14.2.e013055.48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062607452307000_14.2.e013055.49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","article-title":"Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026062607452307000_14.2.e013055.50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026062607452307000_14.2.e013055.51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006235","article-title":"Adding liposomal doxorubicin enhances the abscopal effect induced by radiation\/\u03b1PD1 therapy depending on tumor cell mitochondrial DNA and cGAS\/STING","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026062607452307000_14.2.e013055.52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1591"},{"key":"2026062607452307000_14.2.e013055.53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature New Biol"},{"key":"2026062607452307000_14.2.e013055.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-02015-4"},{"key":"2026062607452307000_14.2.e013055.55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2025-000732","article-title":"Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials","volume":"4","author":"Urias","year":"2025","journal-title":"bmjonc"},{"key":"2026062607452307000_14.2.e013055.56","doi-asserted-by":"publisher","DOI":"10.1016\/S 1470-2045 (21)00658-6"},{"key":"2026062607452307000_14.2.e013055.57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001302","article-title":"Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study","volume":"8","author":"Pakkala","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062607452307000_14.2.e013055.58","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2025.43.16_suppl.5018","article-title":"CA209-8TY trial, a randomized phase 2 trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in metastatic castration-resistant prostate cancer","volume":"43","author":"Eefsen","year":"2025","journal-title":"JCO"},{"key":"2026062607452307000_14.2.e013055.59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026062607452307000_14.2.e013055.60","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2023.41.16_suppl.3584","article-title":"A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer","volume":"41","author":"Koenig","year":"2023","journal-title":"JCO"},{"key":"2026062607452307000_14.2.e013055.61","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"2026062607452307000_14.2.e013055.62","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO-24-01580","article-title":"Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer","volume":"43","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:39Z","timestamp":1782485139000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013055"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013055","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}